JP2011526249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526249A5 JP2011526249A5 JP2011515029A JP2011515029A JP2011526249A5 JP 2011526249 A5 JP2011526249 A5 JP 2011526249A5 JP 2011515029 A JP2011515029 A JP 2011515029A JP 2011515029 A JP2011515029 A JP 2011515029A JP 2011526249 A5 JP2011526249 A5 JP 2011526249A5
- Authority
- JP
- Japan
- Prior art keywords
- residues
- residue
- antibody
- region
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 210000004897 n-terminal region Anatomy 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 7
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 239000000178 monomer Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000006317 isomerization reaction Methods 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008903451 | 2008-07-04 | ||
| AU2008903451A AU2008903451A0 (en) | 2008-07-04 | Composite peptide | |
| PCT/AU2009/000869 WO2010000041A1 (en) | 2008-07-04 | 2009-07-03 | Anti- p2x7 peptides and epitopes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014222949A Division JP2015038144A (ja) | 2008-07-04 | 2014-10-31 | 抗ｐ２ｘ７ペプチドおよびエピトープ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011526249A JP2011526249A (ja) | 2011-10-06 |
| JP2011526249A5 true JP2011526249A5 (enExample) | 2013-10-24 |
| JP5701752B2 JP5701752B2 (ja) | 2015-04-15 |
Family
ID=41465424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515029A Active JP5701752B2 (ja) | 2008-07-04 | 2009-07-03 | 抗ｐ２ｘ７ペプチドおよびエピトープ |
| JP2014222949A Pending JP2015038144A (ja) | 2008-07-04 | 2014-10-31 | 抗ｐ２ｘ７ペプチドおよびエピトープ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014222949A Pending JP2015038144A (ja) | 2008-07-04 | 2014-10-31 | 抗ｐ２ｘ７ペプチドおよびエピトープ |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8597643B2 (enExample) |
| EP (1) | EP2318438B1 (enExample) |
| JP (2) | JP5701752B2 (enExample) |
| KR (1) | KR101701300B1 (enExample) |
| CN (1) | CN102143978B (enExample) |
| AU (1) | AU2009266430B2 (enExample) |
| BR (1) | BRPI0915367B8 (enExample) |
| CA (1) | CA2729868C (enExample) |
| ES (1) | ES2610225T3 (enExample) |
| IL (2) | IL210220A (enExample) |
| NZ (1) | NZ590146A (enExample) |
| WO (1) | WO2010000041A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101555283B (zh) | 2001-01-17 | 2012-03-21 | 生物权威国际有限公司 | 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途 |
| JP5670192B2 (ja) | 2007-09-14 | 2015-02-18 | バイオセプター・インターナショナル・リミテッド | 新規ｐ２ｘ７エピトープ |
| WO2009033234A1 (en) | 2007-09-14 | 2009-03-19 | Biosceptre International Limited | Purinergic (p2x) receptors in extra-cellular body fluid |
| AU2009266430B2 (en) | 2008-07-04 | 2014-08-14 | Biosceptre International Limited | Anti- P2X7 peptides and epitopes |
| EP3395832B1 (en) | 2009-08-20 | 2021-11-24 | Biosceptre (Aust) Pty Ltd | Anti p2x7 receptor antibodies and fragments thereof |
| EP2516470B1 (en) | 2009-12-24 | 2018-02-07 | Biosceptre (Aust) Pty Ltd | Antibodies to non-functional oligomeric p2x7 receptors |
| WO2012031333A1 (en) | 2010-09-10 | 2012-03-15 | Biosceptre International Limited | Companion animal treatments |
| WO2013003895A1 (en) * | 2011-07-01 | 2013-01-10 | Biosceptre International Limited | Combination therapy |
| CN107614528A (zh) * | 2015-04-02 | 2018-01-19 | 生物权威（英国）有限公司 | 疼痛治疗 |
| US12121539B2 (en) | 2015-09-11 | 2024-10-22 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| CN109862883A (zh) | 2016-10-21 | 2019-06-07 | 生物权威（英国）有限公司 | 细胞毒性颗粒 |
| AU2019275479B2 (en) | 2018-05-21 | 2022-12-08 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors with modified linker domains and uses thereof |
| BR112023020659A2 (pt) * | 2021-04-08 | 2023-12-05 | Biosceptre Aust Pty Ltd | Métodos para controlar a atividade de célula imune |
| CN120187461A (zh) * | 2022-09-14 | 2025-06-20 | 生物权威(澳大利亚)有限责任公司 | 免疫细胞的体内检测 |
| JP2025531675A (ja) * | 2022-09-14 | 2025-09-25 | バイオセプター （オースト） プロプライエタリー・リミテッド | 操作された免疫細胞の富化 |
| US20260085104A1 (en) * | 2022-09-14 | 2026-03-26 | Biosceptre (Aust) Pty Ltd | Methods of detecting immune cells |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE920765A1 (en) | 1991-03-12 | 1992-09-23 | Scripps Research Inst | Cell surface receptors homologous to coagulation factors v¹and viii |
| EP0760850A1 (en) | 1994-05-27 | 1997-03-12 | Glaxo Group Limited | P2x RECEPTORS (PURINOCEPTOR FAMILY) |
| US5981218A (en) | 1995-08-09 | 1999-11-09 | Bristol-Myers Squibb Company | Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides |
| JP2001521372A (ja) | 1996-04-30 | 2001-11-06 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ヒトＰ２ｘ４レセプタースプライス−変異体 |
| US6303338B1 (en) * | 1996-08-16 | 2001-10-16 | Human Genome Sciences, Inc. | Pancreas-derived plasminogen activator inhibitor |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| JP3885177B2 (ja) | 1997-03-26 | 2007-02-21 | 大塚製薬株式会社 | ヒト遺伝子 |
| US6133434A (en) * | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
| DE69941187D1 (de) * | 1998-06-01 | 2009-09-10 | Agensys Inc | Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen |
| DE19829473C2 (de) * | 1998-07-01 | 2000-08-10 | Magnus Von Knebel Doeberitz Ch | Verfahren zur frühen Diagnose von Carcinomen |
| EP1157038A4 (en) | 1999-02-26 | 2005-01-19 | Smithkline Beecham Corp | CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17) |
| AUPP991199A0 (en) | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
| WO2001030964A2 (en) | 1999-10-22 | 2001-05-03 | Lifespan Biosciences, Inc. | Anti-cancer nucleic acid and protein targets |
| AU2001274902A1 (en) * | 2000-12-06 | 2002-06-18 | Linex Technologies, Inc. | Efficient sharing of capacity by remote stations using circuit switching and packet switching |
| AUPR201500A0 (en) * | 2000-12-11 | 2001-01-11 | Biosceptre Pty Ltd | Methods for identifying pre-neoplastic and neoplastic states in mammals |
| WO2003020762A1 (en) * | 2001-09-03 | 2003-03-13 | Intreat Pty Limited | Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| CN101555283B (zh) * | 2001-01-17 | 2012-03-21 | 生物权威国际有限公司 | 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途 |
| PL1469072T3 (pl) | 2003-04-17 | 2008-03-31 | Affectis Pharmaceuticals Ag | Środki i sposoby diagnozowania i leczenia chorób afektywnych |
| US20090215727A1 (en) * | 2005-05-05 | 2009-08-27 | Medicure International Inc. | Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphate and vitamin b6 related compounds |
| US7767789B2 (en) * | 2005-06-02 | 2010-08-03 | University Hopitals of Cleveland | Truncated proteins as cancer markers |
| WO2007027957A2 (en) | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| WO2008043145A1 (en) * | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Hybridomas producing antibodies against non functional p2x7 receptor |
| US20100036101A1 (en) * | 2006-10-10 | 2010-02-11 | Angus Gidley-Baird | Antibodies against non functional p2x7 receptor |
| JP5670192B2 (ja) | 2007-09-14 | 2015-02-18 | バイオセプター・インターナショナル・リミテッド | 新規ｐ２ｘ７エピトープ |
| WO2009033234A1 (en) | 2007-09-14 | 2009-03-19 | Biosceptre International Limited | Purinergic (p2x) receptors in extra-cellular body fluid |
| AU2009266430B2 (en) | 2008-07-04 | 2014-08-14 | Biosceptre International Limited | Anti- P2X7 peptides and epitopes |
| EP3395832B1 (en) * | 2009-08-20 | 2021-11-24 | Biosceptre (Aust) Pty Ltd | Anti p2x7 receptor antibodies and fragments thereof |
| EP2516470B1 (en) | 2009-12-24 | 2018-02-07 | Biosceptre (Aust) Pty Ltd | Antibodies to non-functional oligomeric p2x7 receptors |
| WO2011131472A1 (en) | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| WO2012031333A1 (en) | 2010-09-10 | 2012-03-15 | Biosceptre International Limited | Companion animal treatments |
| WO2013003895A1 (en) | 2011-07-01 | 2013-01-10 | Biosceptre International Limited | Combination therapy |
-
2009
- 2009-07-03 AU AU2009266430A patent/AU2009266430B2/en active Active
- 2009-07-03 KR KR1020117002763A patent/KR101701300B1/ko active Active
- 2009-07-03 JP JP2011515029A patent/JP5701752B2/ja active Active
- 2009-07-03 NZ NZ590146A patent/NZ590146A/xx unknown
- 2009-07-03 ES ES09771858.9T patent/ES2610225T3/es active Active
- 2009-07-03 BR BRPI0915367A patent/BRPI0915367B8/pt active IP Right Grant
- 2009-07-03 WO PCT/AU2009/000869 patent/WO2010000041A1/en not_active Ceased
- 2009-07-03 CN CN200980134521.3A patent/CN102143978B/zh active Active
- 2009-07-03 CA CA2729868A patent/CA2729868C/en active Active
- 2009-07-03 US US13/002,647 patent/US8597643B2/en active Active
- 2009-07-03 EP EP09771858.9A patent/EP2318438B1/en active Active
-
2010
- 2010-12-23 IL IL210220A patent/IL210220A/en active IP Right Grant
-
2013
- 2013-10-30 US US14/067,873 patent/US9328155B2/en active Active
-
2014
- 2014-04-30 IL IL232394A patent/IL232394A/en active IP Right Grant
- 2014-10-31 JP JP2014222949A patent/JP2015038144A/ja active Pending
-
2016
- 2016-03-30 US US15/085,929 patent/US10238716B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504578A5 (enExample) | ||
| JP2020524661A5 (enExample) | ||
| HRP20191341T1 (hr) | Protutijela koja vežu ljudski cgrp receptor | |
| JP2019116474A5 (enExample) | ||
| JP2013515508A5 (enExample) | ||
| JP2020114210A5 (enExample) | ||
| JP2021503455A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| US20240209082A1 (en) | Anti-cd96 antibodies and methods of use thereof | |
| JP2020517287A5 (enExample) | ||
| IL295295A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| JP2018517431A5 (enExample) | ||
| JP2019504032A5 (enExample) | ||
| JP2009518005A5 (enExample) | ||
| JP2009240323A5 (enExample) | ||
| JP2010502183A5 (enExample) | ||
| JP2012530487A5 (enExample) | ||
| JP2020505919A5 (enExample) | ||
| CN115605511A (zh) | 抗tigit的抗体、其制备方法和应用 | |
| RU2010149746A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2018509907A5 (enExample) | ||
| JP2005507635A5 (enExample) | ||
| JP2017520575A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2013506428A5 (enExample) |